The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of cixutumumab (IMC-A12) in thymic malignancies.
Arun Rajan
No relevant relationships to disclose
Gregory J. Riely
Consultant or Advisory Role - Abbott Laboratories; ARIAD; Chugai Pharma; Daiichi Sankyo; Tragara
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Infinity; Merck; Pfizer
Corey Allan Carter
No relevant relationships to disclose
Anish Thomas
No relevant relationships to disclose
Sean Khozin
No relevant relationships to disclose
Isabella Bergagnini
No relevant relationships to disclose
Arlene W Berman
No relevant relationships to disclose
Barbara Scepura
No relevant relationships to disclose
Eva Szabo
No relevant relationships to disclose
Min-Jung Lee
No relevant relationships to disclose
Jane B. Trepel
No relevant relationships to disclose
Sarah K Browne
No relevant relationships to disclose
Minjal J Pancholi
No relevant relationships to disclose
Liang Cao
No relevant relationships to disclose
Helen X. Chen
No relevant relationships to disclose
Giuseppe Giaccone
No relevant relationships to disclose